Filter posts

#BIO2019: The State of the Vaccine Industry: Stimulating Sustainable Growth

There’s little doubt that vaccines are one of the most important medical advances ever created. …

#BIO2019: Taking the Pulse of Dealmakers: 2019 Outlook

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year …

#BIOCEO19: We’re Out of Time to Address the Dire Market Failures in Antimicrobial Resistance

Here’s a statistic you might not have known: an estimated 700,000 people die each year …

BIO Investor Forum Explores “Digiceuticals” as a New Class of FDA-Approved Therapeutics

Within the past year, the FDA has launched a provider pre-certification program as a pilot …

Four Questions for the Energy and Commerce Hearing on 340B

Later this morning, the House Energy and Commerce Committee will hold a hearing to examine …

FDA Protects Patients While Promoting Innovation

Today, 83 percent of children with cancer survive, compared to just 58 percent in the …

Next Generation Approaches to Battling Pain and Addiction

What are the new and emerging scientific insights and approaches that offer hope for non-addictive …

#BIOCEO18: Tackling the Opioid Crisis

Opioid addiction is plaguing communities across the country, leaving in its wake countless victims, devastated …

#BIOCEO18: Paradigm Shift Creating New Opportunities in China

The past few years have been a time of tremendous change in the world’s second …

ICYMI: WSJ Editors on “Biotech’s Breakthrough Year”

2017 was an amazing year for biomedical advances, with 46 novel drug approvals, a near …